Abstract

AN OVERVIEW OF ERTUGLIFLOZIN IN TREATMENT OF DIABETES MELLITUS

Diksha Chandwani, Ratana Ram, Mudit Bhardwaj, Vijaya Mishra, Jahid Khan Aashutosh Sinwal*

.

Abstract

A family of oral medications known as SGLT2 inhibitors has shown little success in treating type 2 diabetes. Enthusiastically belonging to the sodium-glucose cotransporter-2 (SGLT2) family, ertugliflozin is a new pharmacological approach to the management of type 2 diabetes patients. Lowering the risk of cardiovascular complications associated with diabetic mellitus (DM), kidneys, microvascular system, and macrovascular system is its main goal. It does not require insulin to function; instead, it raises glucose excretion in urine. The direct action on the kidneys by these medications constitutes a new paradigm in treatment. Hypoglycemia is a small concern, but pancreatic beta cell overstimulation is not scientific studies have shownthe use of SGLT-2 inhibitors can reduce the risk of Cardio vascular disease (CVD) in diabetics. Knowing how ertugliflozin affects the kidneys is crucial. It is recommended by the FDA to increase the starting dose from 5 mg oncea day up to 15 mg once a day in cases when tighter management of blood sugar is necessary, provided that the medication is well-tolerated. Among ertugflozin's most common adverse effects include hypovolemia and UTIs. Ertugliflozin can help type 2 diabetes patients when used with other drugs since it has a synergistic effect.

Keywords: SGLT-2 inhibitor, Ertugliflozin, type 2 diabetes, CVD.